Olanzapine and samidorphan combination treatment: A systematic review.

奥氮平 医学 精神分裂症(面向对象编程) 抗精神病药 精神科 临床试验 内科学 随机对照试验 非定型抗精神病薬 梅德林
作者
Muhammad Youshay Jawad,Yazen Alnefeesi,Leanna M W Lui,Felicia Ceban,David C J Chen-Li,Kayla Teopiz,Saja Jaberi,Emily S Gillissie,Joshua D Di Vincenzo,Joshua D Rosenblat,Roger S McIntyre
出处
期刊:Journal of Affective Disorders [Elsevier BV]
卷期号:301: 99-106
标识
DOI:10.1016/j.jad.2022.01.004
摘要

The overarching aim of this review is to synthesize the efficacy, tolerability, and weight-mitigation effects of the olanzapine/samidorphan (OLZ/SAM) combination treatment in adults with schizophrenia and bipolar disorder-I.A systematic search of PubMed, Web of Science, Embase, and The Cochrane Library was conducted on August 15th, 2021. Studies were included if they investigated the use of OLZ/SAM treatment in patients with schizophrenia or bipolar disorder-I, and reported the clinical outcomes: efficacy, change in weight or waist circumference, tolerability, pharmacokinetics, or change in metabolic parameters. A narrative synthesis was undertaken of the data.Eight studies met the inclusion criteria. All identified studies were conducted in adults with schizophrenia. Compared to OLZ-monotherapy, OLZ/SAM was associated with decreased odds of developing clinically significant (>10%) weight gain (OR=0.50, 95% CI:0.31,0.80; p= 0.003) and increase in waist circumference (risk difference = -17.1% 95% CI:-26.3,-7.8) from baseline measurements respectively. In another study, OLZ was 2.7 times more associated with clinically significant weight gain as compared to OLZ/SAM (OR=2.73, 95% CI:1.11, 6.67; p = 0.023). The clinical efficacy of OLZ/SAM remained similar to OLZ with improved tolerability in both short- and long-term studies with no significantly altered pharmacokinetic properties of the constituent agents.OLZ/SAM-treatment is associated with mitigated weight-gain liability when compared to OLZ-monotherapy in adults with schizophrenia. Additional studies are needed to ascertain patient acceptability, appropriate selection and sequencing of OLZ/SAM in the treatment algorithms for adults with schizophrenia (and BD-I), as well as to determine cost-effectiveness and long-term metabolic effects.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
aiyouwei完成签到,获得积分10
刚刚
大豆大豆不说话完成签到,获得积分10
刚刚
飞鱼完成签到,获得积分10
1秒前
1秒前
2秒前
fx完成签到 ,获得积分10
2秒前
zhutu完成签到,获得积分10
2秒前
潇洒的白昼完成签到,获得积分10
2秒前
xyq完成签到 ,获得积分10
3秒前
windli完成签到,获得积分10
3秒前
roywin完成签到,获得积分10
4秒前
隐形的979发布了新的文献求助10
5秒前
sci完成签到 ,获得积分10
6秒前
Linky完成签到 ,获得积分10
6秒前
cq发布了新的文献求助10
6秒前
凶狠的半山完成签到,获得积分10
6秒前
量子猫完成签到 ,获得积分10
7秒前
Lam完成签到,获得积分10
7秒前
刘威发布了新的文献求助10
8秒前
张三完成签到,获得积分10
8秒前
9秒前
Zephyr完成签到 ,获得积分10
10秒前
875259完成签到,获得积分10
10秒前
10秒前
SciGPT的应助被lancerimpp采纳,获得10
11秒前
Dan完成签到,获得积分10
11秒前
wellforever完成签到 ,获得积分10
12秒前
ma完成签到 ,获得积分10
13秒前
我是老大的应助被小暴采纳,获得10
13秒前
凌凌凌完成签到,获得积分10
14秒前
kongzhiqiqi完成签到,获得积分10
14秒前
yyp完成签到,获得积分10
14秒前
14秒前
菜菜完成签到 ,获得积分10
14秒前
16秒前
余香的应助被windli采纳,获得10
18秒前
324完成签到,获得积分10
18秒前
B_lue完成签到 ,获得积分10
19秒前
赵浩宇完成签到,获得积分10
19秒前
资格丘二完成签到,获得积分0
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180111
求助须知:如何正确求助?哪些是违规求助? 9570235
关于积分的说明 21809184
捐赠科研通 7776198
什么是DOI,文献DOI怎么找? 3433262
关于科研通互助平台的介绍 2557463
邀请新用户注册赠送积分活动 2479039